Core Viewpoint - Teva Pharmaceutical Industries Ltd. has announced the pricing and early acceptance results of its tender offers to purchase outstanding notes issued by its finance subsidiaries, with specific terms and conditions outlined in the Offer to Purchase dated May 19, 2025 [1][10]. Summary by Relevant Sections Tender Offer Details - The early acceptance results indicate the total consideration for each series of notes, with specific amounts tendered and accepted [2][8]. - The total maximum amount and pool tender caps for the offers are set at $1,550 million for Pool 1, $350 million for Pool 2, and $400 million for Pool 3 [2][3]. Acceptance Priority Levels - Notes tendered with Acceptance Priority Level 4 will be accepted in full without proration, while those with Levels 1, 2, and 5 will be accepted subject to proration factors of approximately 60.75%, 39.46%, and 36.66%, respectively [8][9]. Financial Conditions - The settlement of Teva's $2.3 billion senior notes offering on May 28, 2025, satisfied the financing condition for the tender offers [12]. - The purchase price for the Dollar Notes and Euro Notes will be paid in their respective currencies [12]. Timeline and Conditions - The initial settlement date is expected to occur on June 5, 2025, with the offers set to expire at 5:00 p.m. Eastern Time on June 17, 2025, unless extended or terminated earlier [11][9]. - Teva reserves the right to amend or waive conditions related to the offers [10]. Company Overview - Teva Pharmaceutical Industries Ltd. operates as a global biopharmaceutical leader, focusing on innovation and the production of generics and biologics, with a commitment to advancing health for over 120 years [16].